Gene 'may have shown Acomplia risk' - Pharmacy Europe
Gene 'may have shown Acomplia risk'Pharmacy EuropeAcomplia, produced by Sanofi-Aventis, had to be withdrawn because people taking part in a trial of the drug started killing themselves.
Takeda Snags Orexigen's Obesity Drug in $1B-Plus Deal - BioWorld Online
Genetic Engineering NewsTakeda Snags Orexigen's Obesity Drug in $1B-Plus DealBioWorld OnlineAcomplia is not approved in the US and was withdrawn from the FDA registration process in 2007 after negative feedback from an FDA advisory panel.
The Case Of Acomplia Highlights The Importance Of Genetic Testing - Pharmaceuticals & Healthcare Insight (registration)
The Case Of Acomplia Highlights The Importance Of Genetic TestingPharmaceuticals & Healthcare Insight (registration)Acomplia was once one of Sanofi-Aventis's potential blockbuster drugs, with annual sales forecast to be more than US$5bn by 2010 - especially as the .
Arena's Lorcaserin: Weighed Down by Qnexa and Meridia - Seeking Alpha (blog)
Arena's Lorcaserin: Weighed Down by Qnexa and MeridiaSeeking Alpha (blog)In June 2007, the FDA rejected Sanofi-Aventis' (SNY) Acomplia saying that the drug's benefits did not outweigh its risks.
The new diet pills: fad, fact or fiction? - MarketWatch
The new diet pills: fad, fact or fiction?MarketWatchA couple of years ago, Sanofi-Aventis finally abandoned its weight-loss drug Acomplia, also known as rimonabant, after European and US regulators voiced .
